Clinical Trial Update: Phase II Study of Alternating Sunitinib and Temsirolimus [Phase 2]

View source ↗

Summary

Phase II study evaluating alternating sunitinib and temsirolimus in metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-09-21